Histone H2AX phosphorylated at Ser139 (g-H2AX) is a useful biomarker for DNA double-strand breaks. However, g-H2AX detection has methodological disadvantages such as the requirement of expensive anti-g-H2AX antibody and time-consuming handling for its staining. Mediator of DNA damage checkpoint 1 (MDC1) is a central adaptor protein which recruits various DNA damage response proteins to g-H2AX and thus forms nuclear foci in the same location as g-H2AX in response to DNA damage. Here, we describe an easy-to-use genotoxicity assay which combines enhanced green ‰uorescence protein (EGFP)-fused MDC1-expressing cells with a free R program for image-processing and quantiˆcation of foci area/nucleus. The work‰ow of this assay is simple: mutagen treatment, imaging, and R-processing. This assay does not need antibodies or staining handling and it detected the genotoxicity of a range of mutagens, including camptothecin (topoisomerase I inhibitior), cisplatin (crosslinker), and 4-nitroquinoline 1-oxide and benzo[a]pyrene (bulky DNA-adduct forming compounds), as increased ‰uorescence of EGFP-MDC1 foci. Furthermore, cotreatment with arabinofuranosyl cytosine/hydroxyurea and mutagens sensitized EGFP-MDC1 foci formation to bulky DNA adduct-type mutagens. Additionally, the established cells can be monitored in real-time using live cell imaging to obtain detailed dynamics of MDC1 in response to mutagens. The simple handling of this assay is expected to enable its full automation, thus making it useful for high-throughput genotoxicity screening of chemicals and monitoring of environmental mutagens.
Introduction
Histone H2AX phosphorylated at Ser139 (g-H2AX) is one of the most useful biomarkers for DNA doublestrand breaks (DSBs). When DSBs are induced in cells, H2AX polypeptides within about ¿2 Mbp of a DSB site are phosphorylated to form g-H2AX nuclear aggregates called foci (1, 2) . Because a single g-H2AX focus corresponds to one DSB (2,3), g-H2AX is an extremely sensitive indicator for DSBs. Whereas induction of g-H2AX wasˆrst shown in response to ionizing irradiation (1) , it has since been reported that a broad spectrum of mutagens also induces g-H2AX, including radical generators [bleomycin (4) , tirapazamine (4), calicheamicin g1 (5), c-1027 (6) , and neocarzinostatin (7)], topoisomerase inhibitors [camptothecin (CPT) (6) , topotecan (8) , and etoposide (4)], a DNA intercalator [doxorubicin (9) ], alkylating agents [N-methyl-Nnitrosourea (MNU) (10) , N-methyl-N?-nitro-Nnitrosoguanidine (11), adzelesin (6) , methyl methanesulfonate (12) , and N-ethyl-N-nitrosourea (13) ], an oxidizing agent [hydrogen peroxide (7) ], bulky DNA adduct-forming agents [4-nitroquinoline1-oxide (4NQO) (4), benzo[a]pyrene (B[a]P) (13) , and N-acetoxy-2-acetylamino‰uorene (13)], DNA crosslinking agents [cisplatin (CDDP) (14) and actinomycin D (15) ], a ribonucleotide reductase inhibitor [hydroxyurea (HU) (16) ], a DNA polymerase inhibitor [aphidicolin (17) ], and a general tyrosine kinase inhibitor [staurosporine (18) ]. Furthermore, the relationship between chemical dose and g-H2AX induction is linear (4) . These facts explain why there is increasing interest in using g-H2AX as a biomarker in chemical genotoxicity assays. Indeed, previous studies have used g-H2AX in genotoxicity assays for photogenotoxic chemicals (19, 20) and for known and potential environmental pollutants such as benzene (21) , polyaromatic hydrocarbons (22) , nonylphenol polyethoxylates (23) , heavy metals (24) , cigarette smoke (25) , and nanoparticles (26) (27) (28) (29) (30) (31) (32) , and the results were all positive except for alumina (Al2O3) nanoparticles.
On the other hand, genotoxicity assays targeting g-H2AX still have several methodological limitations. Immuno‰uorescence microscopy, ‰ow cytometry, western blotting, and enzyme-linked immunosorbent assay (ELISA) are conventionally used for g-H2AX detection, and all these methods absolutely require anti-g-H2AX antibody, which is an expensive consumable. Furthermore, staining with g-H2AX antibody is also burdensome and time consuming and high-throughput screening with these methods would be di‹cult. For environmental and chemical management applications, an easy-to-use and high-throughput method for chemical genotoxicity screening would be advantageous.
Mediator of DNA damage checkpoint 1 (MDC1) is a large protein (2,089 amino acids) (33) which plays a central role in ampliˆcation and mediation of the DNA damage response (DDR). In human cells, when a DSB occurs, the MRN complex composed of MRE11 (meiotic recombination 11)/RAD50 (homolog of S. cerevisiae's Rad50)/NBS1 (Nijmegen breakage syndrome protein 1) binds to the DSB site (34) , whereupon ataxia telangiectasia mutated (ATM) protein is recruited to the DNA lesion via NBS1 (35, 36) . ATM phosphorylates histone H2AX adjacent to the DSB site to form g-H2AX (37) . At the same time, DNA-dependent protein kinase (DNA-PK) is also recruited to the DSB site and phosphorylates H2AX (38) . Subsequently, MDC1 binds to g-H2AX (39) and brings additional ATM to the DSB site, expanding ATM-dependent H2AX phosphorylation (40) . The positive feedback loop involving ATM-g-H2AX-MDC1 ampliˆes DDR signaling. In the case of replication stress, ATM and rad3-related (ATR) protein phosphorylates H2AX at stalled replication forks (9, 16) . A recent report demonstrated that MDC1 binds to topoisomerase II binding protein 1 (TopBP1) and that both H2AX and MDC1 are required for formation of TopBP1 foci at stalled replication forks (41) , suggesting a role for MDC1 in response to replication stress. By these mechanisms, MDC1 immediately (within 5 min after ionizing irradiation) forms foci in the same locations as those formed by g-H2AX in response to DSBs (2, 42) .
MDC1 has multiple domains for mediating protein-protein interactions and thus functions as an important adaptor which brings and retains various DDR proteins to DSB sites through g-H2AX. The N-terminal forkhead-associated domain interacts with Ser1981-phosphorylated ATM (40, 43) and Thr68-phosphorylated checkpoint kinase 2 (Chk2) (44) in response to DSBs and constitutively with RAD51 recombinase (45) ; the Ser-Asp-Thr repeats constitutively phosphorylated by casein kinase 2 interact with NBS1 (46) (47) (48) (49) ; the Thr-GlnXaa-Phe repeats phosphorylated by ATM in response to DSBs interact with ringˆnger protein 8 (50) (51) (52) ; the Pro/Ser/Thr repeats interact with DNA-PK (53); and the tandem BRCA1 C-terminus (BRCT) domains interact with g-H2AX (39,40), p53 (54), p53-binding protein 1 (55) , cell division cycle 27 (56), murine double minute 2 (57), and Ser 1524-phosphorylated topoisomerase IIa (58) .
Here, we established human cells expressing enhanced green ‰uorescent protein (EGFP)-fused MDC1 (EGFP-MDC1) and developed an easy-to-use and rapid genotoxicity assay, which combines both the cells and a free R program for imaging and statistical analysis (59) . We then demonstrated the e‹cacy of the genotoxicity assay by testing several diŠerent types of mutagens, including the DNA topoisomerase inhibitor CPT, the crosslinking agent CDDP, the bulky adduct-forming compounds 4NQO and B[a]P, and the alkylating agent MNU.
Materials and Methods
Chemicals: Dimethyl sulfoxide (DMSO), MNU, arabinofuranosyl cytosine (AraC) and HU were purchased from Wako (Osaka, Japan). CDDP and CPT were purchased from Sigma-Aldrich (Missouri, USA). 4NQO and B[a]P were purchased from Nacalai Tesque (Kyoto, Japan). O 6 -benzylguanine (O 6 -BG) was purchased from Santa Cruz (California, USA). The chemicals were dissolved in DMSO.
Cell culture: Human breast adenocarcinoma MCF7 cells were cultured in Dulbecco's Modiˆed Eagle's Medium supplemented with 10z fetal bovine serum at 379 C in a humidiˆed 5z CO2 incubator.
Construction of pEGFP-C1/MDC1 plasmid: First, the middle region of human MDC1 cDNA (KIAA0170) were cut out with HindIII and EcoRI and inserted into the same sites of pEGFP-C1 vector (Clontech, California, USA) (pEGFP-C1/MDC1 DNDC). Next, the 3? terminus region of human MDC1 was ampliˆed from human MDC1 cDNA by polymerase chain reaction (PCR) with the following primers: 3? terminus MDC1-F, 5?-ccggaattccaatctcctgtcaccacagaccag-3? (an EcoRI site is underlined); 3? terminus MDC1-R, 5?-tccccgcgg tcaggtggatgacatctccaaagggg-3? (a SacII site is underlined). The PCR product was cut with EcoRI and SacII and inserted into pEGFP-C1/MDC1 DNDC cut with the same restriction enzymes (pEGFP-C1/MDC1 DN). Subsequently, the 5? terminus region of human MDC1 was ampliˆed from human MDC1 cDNA by PCR with the following primers: 5? terminus MDC1-F, 5?-ccc aagcttccgaggacacccaggctattgactgg-3? (a HindIII site is underlined); 5? terminus MDC1-R, 5?-cccaagctt ggcttttctccagagggacagcc-3? (a HindIII site is underlined). The PCR product was cut with HindIII and inserted into pEGFP-C1/MDC1 DN cut with the same restriction enzyme (pEGFP-C1/MDC1).
Transduction of stable EGFP-MDC1-expressing MCF7 (EGFP-MDC1/MCF7) cells: pEGFP-C1/ MDC1 was transfected into MCF7 cells by Lipofecta-mine 2000 (Life technologies, California, USA) according to the manufacturer's protocol. After 48 h, stable transformants were selected using medium supplemented with 1 mg/ml G418.
Immunoprecipitation: Cells grown to 80z con‰uence in 100 mm dishes were suspended into 1 mL icecold phosphate-buŠered saline (PBS) (137 mM NaCl, 2.68 mM KCl, 8.10 mM Na2HPO4, and 1.67 mM NaH2PO4) and pelleted by centrifugation at 1,000 rpm for 1 min at 49 C. Cell pellets were resuspended in 1 mL ice-cold cell lysis buŠer (150 mM NaCl, 10 mM TrisHCl pH 7.3, 0.5 mM ethylenediaminetetraacetic acid, 1 mM beta-mercaptoethanol, 0.2 mM phenylmethylsulfonyl ‰uoride, 10 mM beta-glycerophosphate, and 1z NP-40) and incubated for 20 min on ice. Lysate was centrifuged at 15,000 rpm for 15 min at 49 C. 65 mL of the supernatant was saved as a whole-cell lysate (Input) sample and the remaining supernatant was used for immunoprecipitation. 1 mL anti-GFP antibody (ab290, Abcam, Cambridge, UK) was added to the supernatant and the sample was rotated for 60 min at 49 C. Next, after addition of 20 mL of a 50z slurry of Protein A agarose (Merck Millipore, Massachusetts, USA), the sample was rotated for 60 min at 49 C. The sample was pelleted by centrifugation at 8,000 rpm for 1 min at 49 C. Pellets were washed with 500 mL ice-cold cell lysis buŠer three times and then analyzed by Western blotting as immunoprecipitated (IP) samples.
Western blotting: Input or IP sample was denatured in NuPAGE LDS Sample BuŠer (Life technologies) at 709 C for 10 min. For IP samples, each sample was pelleted by centrifugation at 15,000 rpm for 1 min and the supernatant was diluted ten-fold with NuPAGE LDS Sample BuŠer. To separate proteins, 3 mL/sample was applied to each well of a NuPAGE Novex 4-12z Bis-Tris Gel (Life technologies) and electrophoresis was performed in NuPAGE MES SDS Running BuŠer (Life technologies) at 200 V for 60 min. Separated proteins were blotted onto Hybond ECL membrane (GE Healthcare, Buckinghamshire, UK) by electrophoresis (100 V for 90 min in blotting buŠer (20z methanol, 25 mM Tris, and 192 mM glycine)). The membrane was incubated for 60 min with 5z skimmed milk in TBS-T (137 mM NaCl, 20 mM Tris-HCl pH 7.6, 0.1z Tween 20) for blocking. Next, the membrane was incubated for 60 min with anti-MDC1 antibody (1:1,000) (ab11169, Abcam) or anti-GFP antibody (1:1,000) (ab290, Abcam) in TBS-T. Subsequently, the membrane was incubated for 60 min with horseradish peroxidase-conjugated goat anti-rabbit antibody (1:10,000) (#7074, Cell Signaling Technology, Massachusetts, USA) in TBS-T. To develop chemiluminescence by horseradish peroxidase, the membrane was incubated for 5 min with ECL Prime WB Detection Reagent (GE Healthcare). Chemiluminescence detection was performed using an LAS-1000 image analyzer controlled by Image Reader LAS-1000 Mini V1.21 software (Fujiˆlm, Tokyo, Japan).
Immuno‰uorescence staining and microscopy: For immuno‰uorescence staining, EGFP-MDC1-expressing MCF7 cells (2×10 5 ) were seeded onto a 24×24 mm 2 cover glass (Matsunami glass, Osaka, Japan) in each well of a 6-well plate and treated with 10 mM CPT for 1 h. CPT dissolved in DMSO were added to the medium directly and theˆnal DMSO concentration was 0.1z (v/v). After experimental treatment, subsequent incubation was performed in the dark as much as possible. Cells wereˆxed with 4z formaldehyde in PBS for 10 min and permeabilized with 0.2z Triton X-100 in PBS for 10 min. Next, cells were incubated in 4z bovine serum albumin in PBS for 30 min for blocking. Cells were incubated for 60 min with anti-MDC1 antibody (1:100) (ab11169) or anti-g-H2AX antibody (1:100) (a component of the OxiSelect DNA Double Strand Break (DSB) Staining Kit, Cell Biolabs, California, USA) in 1z BSA in PBS. As a negative control, an equal concentration of normal rabbit IgG (sc-2027, Santa Cruz) or normal mouse IgG (sc-2025, Santa Cruz) diluted with 1z BSA in PBS was used. Subsequently, cells were incubated for 60 min with tetramethylrhodamine-5-(and 6)-isothiocyanate (TRITC)-conjugated goat anti-rabbit (1:200) (ab6718, Abcam) or TRITCconjugated goat anti-mouse IgG (ab7065, Abcam). Nuclei were stained for 10 min with 0.5 mg/mL Hoechst 33342. Microscopic observations were performed using a BZ-9000 ‰uorescence microscope (Keyence, Osaka, Japan). A 20× (Plan Apo/0.75 numerical aperture) objective was used. Image processing was performed by using a BZ-II Analyzer (Keyence).
Programming in R: After microscopic imaging, TIF-images were converted to JPG-images using BZ-II Resizer (Keyence) to reduceˆle sizes. Image-processing and statistical analysis were processed in R, and imageprocessing was performed using the EBImage package (60) . JPG-images for each individual treatment were separately placed into diŠerent R-work folders. Work‰ow of the program using R is shown in Fig. 2A . The detailed program was described in supplemental information (Available at https://www.jstage.jst.go.jp/ browse/jemsge). Brie‰y, green channels of the EGFP-MDC1 images were converted to gray scale images, brightness of the images was normalized, and nuclei and foci were separately extracted from the same normalized images. In nuclear extraction, the images were binarized and the resulting sets of combined pixels (named objects) were numbered. Based on thresholds of area and acircularity of each object and mean brightness of each nucleus corresponding to each object, noise (objects not corresponding to any nuclei in the normalized images) and objects corresponding to nuclei with weak bright- ness were removed. In foci extraction, the normalized images were binarized using the diŠerent condition from that of nuclear extraction. Finally, total foci area/nucleus was calculated using the extracted nuclei and foci images.
A new genotoxicity assay: EGFP-MDC1/MCF7 cells (2×10 5 ) seeded in 35-mm glass-base dishes were treated with mutagens for various times. The mutagens dissolved in DMSO were added to the medium directly and the maximum ofˆnal DMSO concentration was 0.25z (v/v). In the AraC/HU co-treatment experiment, theˆnal DMSO concentration was 0.4z (v/v). In the O6-BG co-treatment experiment, theˆnal DMSO concentration was 0.35z (v/v). Cells wereˆxed with 4z formaldehyde in PBS for 10 min. After a PBS wash, microscopic observations were performed. A 20× (Plan Apo/0.75 numerical aperture) objective and the quick full-focus function were used. In each experimental condition, 10-15 diŠerentˆelds were imaged and imageprocessing and calculation of foci area/nucleus were performed using R.
Results
To establish EGFP-MDC1/MCF7 cells, pEGFP-C1/MDC1 was transfected into MCF7 cells. Although stable transformants had been selected by G418, the population of EGFP-MDC1-expressing cells observed by ‰uorescence microscopy was very small (about 1z), but cells with a strong EGFP signal were isolated. To conˆrm that full-length EGFP-MDC1 was expressed in the isolated cells, western blotting (WB) following immunoprecipitation (IP) with anti-GFP antibody was performed (Fig. 1A) . In the input sample, anti-MDC1 antibody detected endogenous MDC1 signal located at about 220 kDa in both EGFP-MDC1-transduced cells and negative control cells, whereas an additional MDC1 signal corresponding to a protein larger than endogenous MDC1 was detected only in EGFP-MDC1-transduced cells. The diŠerence in sizes between the endogenous and the larger MDC1 corresponds to the size of EGFP (about 27 kDa). Using anti-GFP antibody, GFP signal was detected only in EGFP-MDC1-transduced cells, and the band was located at the same size as the upper MDC1-signal. After IP with anti-GFP antibody, both GFP and MDC1 signals were detected only in EGFP-MDC1-transduced cells and their locations corresponded to that of the larger MDC1. These results clearly show that full-length EGFP-MDC1 was expressed in EGFP-MDC1-transduced cells and the level of EGFP-MDC1 expression was much higher than that of endogenous MDC1.
We tested whether EGFP-MDC1 expressed in the established EGFP-MDC1/MCF7 cells was functional. Cells were treated with DMSO (negative control) or 10 mM CPT for 1 h and immuno‰uorescence analysis using anti-MDC1 and anti-g-H2AX antibody was performed.
As shown in Fig. 1B , immunostaining with anti-MDC1 antibody produced a diŠuse nuclear signal in DMSOtreated cells but revealed discrete foci in nuclei in response to CPT. Localization of GFP signal completely overlapped with that of the anti-MDC1 signal. Similarly, the signal from anti-g-H2AX antibody was observed as discrete foci and increased in response to CPT (Fig. 1C) . Foci identiˆed by GFP signal overlapped with the anti-g-H2AX signal. Given these facts, we conrmed that EGFP-MDC1 expressed in EGFP-MDC1/MCF7 cells was functional, at least to the extent that EGFP-MDC1 localizes to nuclear foci in response to DNA damage. Next, to quantify EGFP-MDC1 formation after mutagen treatment, we developed an automated program for image-processing using R. The outline of the procedure is shown in Fig. 2A , and works as follows. After mutagen treatment, GFP signal in the cells is imaged by immuno‰uorescence microscopy with vivid clarity. Then, each nucleus area and focus area are separately extracted from the same image (Fig. 2B) , each focus is linked to its corresponding nucleus, and total foci area in each nucleus is calculated using R. The details of the procedure are described in Materials and Methods. Furthermore, we carefully optimized the condition of the image-processing conditions of the program. Using EGFP-MDC1/MCF7 cells and the image-processing program, we established a new genotoxicity assay. The work‰ow is simple: sample treatment,ˆxation (if required), microscopic imaging, and image-processing and calculation of foci area/nucleus using R. We applied the genotoxicity assay to four types of mutagens: CPT (topoisomerase I inhibition), 4NQO (bulky DNA-adduct formation), CDDP (DNA crosslinking), and MNU (DNA alkylation). EGFP-MDC1/MCF7 cells were treated with 10 mM CPT, 10 mM 4NQO, 40 mM CDDP, or 1 mM MNU for 1, 3, or 24 h, and the genotoxicity assay was performed. Representative and all histograms of EGFP-MDC1 foci area/nucleus of normal and damaged cells are shown in Fig. 3A and Supplemental Fig. 1 , clearly illustrating that most DMSO-treated (control) cells have relatively small EGFP-MDC1 foci areas whereas most CPT-treated (damaged) cells have extensive foci areas. As shown in Fig. 3B , CPT or 4NQO exposure signiˆcantly increased the area of EGFP-MDC1 foci after 1 h whereas no obvious changes were detected after CDDP or MNU treatment at 1 h. However, CDDP treatment signiˆcantly increased the area of EGFP-MDC1 foci after 24 h. On the other hand, MNU did not increase the area of EGFP-MDC1 foci after 24 h, the longest time point examined. Next, we tested B[a]P which requires metabolic activation to form bulky DNA adducts. Whereas no increase in the area of EGFP-MDC1 foci was observed in 1 mM B[a]P-treated cells at 1 h and 3 h, a signiˆcant increase was observed 24 h after treatment (Fig. 3C) .
To enhance the sensitivity of EGFP-MDC1/MCF7 cells to mutagens, AraC (DNA polymerase inhibitor) and HU were co-administered with 4NQO or B[a]P. In 4NQO-treated cells, co-treatment with AraC and HU signiˆcantly increased the EGFP-MDC1 foci area (Fig.  4A) . In the case of B[a])P, although signiˆcant EGFP-MDC1 foci formation requires 24 h of treatment ( Fig.  3C and 4B ), co-treatment with AraC and HU signiˆcantly increased EGFP-MDC1 formation after only 3 h treatment (Fig. 4B) . In an attempt to enhance the sensitivity of EGFP-MDC1/MCF7 cells to MNU, which was negative in the genotoxicity assay (Fig. 3B) , 25 mM O 6 -BG was co-administered with MNU. MNU forms alkylated DNA lesions such as O 6 -methylguanine (O 6 -MG) and O 6 -BG is an inhibitor of O 6 -methylguanine DNA methyltransferase (MGMT) which repairs O 6 -MG back to guanine. As shown in Fig. 4C , co-treatment with MNU and O 6 -BG increased EGFP-MDC1 foci formation at both 3 h and 24 h treatment but the increase was not signiˆcant.
Discussion
Here, we established an easy-to-use genotoxicity as-say which combines EGFP-MDC1/MCF7 cells with an automated image-processing program using R software. This assay has several advantages compared with other genotoxicity assays targeting g-H2AX. First, our method does not need any antibodies, which are expensive consumables, whether obtained commercially or prepared in house. Second, our method does not require any staining procedures and thus saves on staining and handling time. Third, the assay accommodates live cell imaging, which enables detection of not only EGFP-MDC1 foci formation but also its detailed dynamic changes in terms of location, size, shape and brightness. CPT, 4NQO, CDDP, and B[a]P are all known inducers of DSBs and g-H2AX (4, 6, 13, 14, (61) (62) (63) (64) , and all induced EGFP-MDC1 foci in our new genotoxicity assay (Fig. 3) . These results suggest that our assay can detect genotoxicity of a range of mutagens.
CPT forms a stable complex with topoisomerase I (Topo I) and DNA to inhibit Topo I (65) and induces a DSB speciˆcally aŠecting the leading strand of the replication fork in S phase of the cell cycle (61) . However, we observed that EGFP-MDC1 foci formed in most cells treated with CPT (data not shown), suggesting that CPT may also induce DSBs at stages other than S phase. Consistent with this possibility, it was reported that CPT also forms a stable CPT-Topo I-DNA complex during transcription (66) and induces DSBs and g-H2AX in post-mitotic cells (67) .
4NQO also induces DSBs (62) and the frequency is not changed through the cell cycle (4). This fact is consistent with our observation that EGFP-MDC1 foci were formed in most cells treated with 4NQO as well as CPT (data not shown). On the other hand, 4NQO most signiˆcantly induces g-H2AX foci in S phase (4), implying that it generates DNA lesions other than DSBs which also induce g-H2AX and MDC1 foci. One possibility is that stalled replication forks unaccompanied by DSBs result in foci formation. It was shown that bulky DNA adducts formed by 4NQO induce stalling of replication forks in yeasts (68) and that stalling of replication forks by mutagens induces ATR-dependent g-H2AX and MDC1 foci (16, 41) . However, at least to our knowledge, it is still unclear what (DSBs, single-strand breaks, or others?) actually induces g-H2AX and MDC1 foci at stalled replication forks.
Bulky DNA adducts formed by mutagens such as 4NQO, B[a]P, and ultraviolet (UV) irradiation are repaired by nucleotide excision repair (NER) (69) (70) (71) (72) . NER is a multistep process that consists of recognition of a DNA lesion, unwinding of the DNA helix around the lesion, dual incision around the lesion, excision of 24-32 nucleotides around the lesion, and gap-ˆlling DNA synthesis (73) . g-H2AX can also be induced in cells in G0/G1 phase in an NER-dependent manner. In this case, H2AX phosphorylation depends not on ATM or DNA-PK but on ATR (74, 75) . After UV irradiation or treatment with N-acetoxy-2-acetylamino‰uorene, which also forms bulky DNA adducts (76), g-H2AX in G0/G1 phase is reduced in NER-defective cells such as xerodrma pigmentosum (XP)-A, XP-C, or XP-G cells, which are defective in formation of the pre-incision complex, recognition of DNA damage, and cleavage on the 3? side of the damaged DNA, respectively (74, 75, 77) . Consistent with this, ectopic expression of wild-type XPA in XP-A cells recovers the g-H2AX induction in G0/G1 phase after UV irradiation (74) . Furthermore, the g-H2AX in G0/G1 phase after UV irradiation is increased by DNA polymerase inhibition with aphidicolin, AraC, or AraC/HU treatment, suggesting that the DNA single-strand gaps formed during NER could eventually induce g-H2AX (74, 75) . We previously utilized AraC/HU for sensitization of DNA strand break detection in a ‰uorometric analysis of DNA unwinding assay (78) . These observations motivated us to test whether AraC/HU treatment would promote EGFP-MDC1 foci formation by bulky DNA adductforming mutagens which are repaired through NER. In fact, AraC/HU treatment increased and accelerated EGFP-MDC1 foci formation in 4NQO-treated and B[a]P-treated cells, respectively (Fig. 4) , suggesting that AraC/HU could sensitize our assay to mutagens repaired through NER. Furthermore, our results strongly indicate that MDC1 participates not only in the cellular responses to DSBs and stalling of replication forks, but also in NER-mediated repair. However, it is unclear whether g-H2AX/MDC1 foci respond to DNA singlestrand gaps or the resultant DSB lesions. If g-H2AX/ MDC1 foci directly respond to the former, then whether g-H2AX/MDC1 foci formation is a general process in NER will need to be elucidated in further studies.
MNU is a simple alkylating mutagen, and one of major DNA lesions induced by MNU is O 6 -MG (79) . MGMT repairs O 6 -MG to guanine by removing the methyl adduct of the base (80, 81) . In this case, any DNA single-strand gaps would not occur and thus there would be no opportunity for g-H2AX/MDC1 foci induction as in NER. Our result, that MNU treatment did not increase EGFP-MDC1 foci (Fig. 3B) , implies an important role for the MGMT repair system. Indeed, MGMT-defective cells induce g-H2AX in response to MNU (10) . These facts encouraged us that MGMT inhibition might sensitize our assay to MNU, and therefore we used the MGMT inhibitor O 6 -BG (82) for this purpose. O 6 -BG binds to MGMT by competing with O 6 -MG and transfers its benzyl group to MGMT, resulting in irreversible inhibition of MGMT (83) . As shown in Fig. 4C , co-treatment with MNU and O 6 -BG increased the area of EGFP-MDC1 foci but the increase was not signiˆcant. It remains a possibility that optimization of O 6 -BG treatment conditions such as O 6 -BG concentra-tion and timing could improve the sensitivity of our assay to MNU. A major repair system of O 6 -MG other than MGMT is mismatch repair (MMR) (84, 85) . Since MMR causes single-strand gaps through repair similar to NER (86) , gaps may induce g-H2AX through MMR as well as through NER.
As is well known, B[a]P requires metabolic activation for genotoxicity expression (87) . In cells, B[a]P activates the transcription factor aryl hydrocarbon receptor which subsequently increases expression of xenobiotic metabolizing enzymes such as cytochrome P450 (CYP) 1A1 and CYP1A2 (88, 89) . These enzymes metabolize B[a]P to produce benzo(a)pyrene diolepoxide (BPDE) which forms a bulky DNA adduct (70, 90) . Thus, there is a time lag between enzyme induction and bulky DNAadduct formation after B[a]P treatment (Supplemental Fig. 2 ). This is consistent with our data, that B[a]P needed 24 h to induce signiˆcant EGFP-MDC1 foci formation whereas the direct mutagen 4NQO required only 1 h (Fig. 3) . Furthermore, this result indicates that the assay can utilize the bioactivation processes of the human cells and thus can detect genotoxicity of some indirect mutagens without supplementary metabolic activation although whether the cells su‹ciently express all kinds of metabolic enzymes has not been tested.
Some mutagens such as UV can induce not only g-H2AX foci but also pan-nuclear distribution of g-H2AX (91). The image-processing program of our genotoxicity assay may not detect the latter response as positive and thus may underestimate the genotoxicity of some mutagens although we have not tested such mutagens yet. Recent report showed that MDC1 binds to ionizing irradiation-induced pan-nuclear g-H2AX, clearly indicating involvement of MDC1 in DDR by pan-nuclear g-H2AX (92) . A detailed observation of cells to detect a change in localization of EGFP-MDC1 between normal and pan-nuclear g-H2AX-forming cells would be required in a further study for improvement of our genotoxicity assay.
The protocol of our assay is simple (mutagen treatment, microscopic imaging, and image-processing and calculation of foci area/nucleus using R). Therefore, we are conˆdent that automation of all the steps can be achieved and thus our assay can be applied to highthroughput genotoxicity screening and monitoring of environmental mutagens.
